TransMedics Director David Weill Purchases $109,000 of Stock -- Should Investors Buy Too?

Key Points The director acquired 1,336 shares for a total value of ~$109,000 on Sept. 11, 2026. The purchase involved shares equal to 9% of the stake held before the filing. The transaction was executed via direct ownership, bringing the total direct position to 16,392 shares. Shares were purchased at $81.63 per share, while the stock was priced at $82.18 at the Sept. 11, 2026, market close. 10 stocks we like better than TransMedics Group › David Weill, a Director at TransMedics Group, Inc. (NASDAQ:TMDX) , purchased 1,336 shares of common stock on Sept. 11, 2026. SEC Form 4 filing Transaction summary Transaction value based on SEC Form 4 weighted average purchase price ($81.63); post-transaction value based on Sept. 11, 2026, market close ($82.18).